Survival prognosis and clinicopathological features of the lymph nodes along the left gastric artery in gastric cancer: implications for D2 lymphadenectomy.

The Japanese Gastric Cancer Treatment Guidelines (third edition) have assigned No. 7 station left gastric artery lymph nodes (LNs) to the D1 range of lymphatic dissection. We investigated the clinicopathological characteristics, survival impact, and appropriateness of ascribing No. 7 station LNs to D1 lymphadenectomy in gastric cancer. Patients (n=608) undergoing radical resection with No. 7 station LN dissection were recruited between January 1997 and June 2008. They were subdivided into four groups: N0, no LN metastasis; D1, LN without No. 7 station LN metastasis in the D1 lymphadenectomy region; No. 7, No. 7 station LN without LN metastasis in the D2 lymphadenectomy region; and D2, LN without No. 7 station LN metastasis in the D2 lymphadenectomy region. Of these, 17.2% (n=105) were positive for No. 7 LN metastasis, an important, independent prognostic factor associated with poor clinicopathological parameters, advanced tumor stage, and reduced survival. Tumor behavior in the No. 7 group was similar to that in the D2 group, but poorer than in the D1 group in terms of advanced tumor stage, with 5-year survival rates of 34.3%, 25.9% and 54.6%, respectively. Five-year survival rates in the No. 7 group were comparable to those in the D2 group (P>0.05), but significantly lower than in the D1 group (P<0.05). Logistic multivariate regression analysis established No. 3 and 9 station LN metastasis, node classification, and tumor-node-metastasis stage as independent risk factors for No. 7 station LN metastasis. Thus, No. 7 station LNs should be ascribed to D2 lymphadenectomy in gastric cancer.

[1]  M. Orringer,et al.  Gastric Cancer, Version 2.2013 , 2013 .

[2]  D. Ichikawa,et al.  Prognostic impact of lymph node metastasis along the left gastric artery in gastric cancer. , 2011, Hepato-Gastroenterology.

[3]  Wei Liu,et al.  Impact of Lymphatic Vessel Invasion on Survival in Curative Resected Gastric Cancer , 2011, Journal of Gastrointestinal Surgery.

[4]  M. S. Subramanya,et al.  Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric Adenocarcinoma , 2011, Annals of surgery.

[5]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[6]  A. Ponti,et al.  Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer , 2010, The British journal of surgery.

[7]  N. Sharma,et al.  An evidence-based medicine review of lymphadenectomy extent for gastric cancer. , 2009, American journal of surgery.

[8]  Y. Mok,et al.  Gastric Cancer histology: Clinicopathologic characteristics and prognostic value , 2008, Journal of surgical oncology.

[9]  F. Wan,et al.  Tumor size: A non‐neglectable independent prognostic factor for gastric cancer , 2008, Journal of surgical oncology.

[10]  Jen-Hao Chen,et al.  Nodal dissection for patients with gastric cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[11]  D. Gouma,et al.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Weeden,et al.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial , 2001 .

[13]  M. Tachibana,et al.  Prognostic Significance of Fas and Fas Ligand System-Associated Apoptosis in Gastric Cancer , 2000, Annals of Surgical Oncology.

[14]  P. Fayers,et al.  Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.

[15]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.

[16]  M. Orringer,et al.  Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.